Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
P11-4 at a glance
- Not injected — read this first
- P11-4 has no human injectable use, no injection dose and no injection safety data. It is applied to a prepared tooth surface by a dentist or a hygienist working on a dentist's prescription. Nothing on this page describes reconstitution or injection, because no such protocol exists for this compound.
- What it is
- An 11-residue rationally designed self-assembling peptide, Ac-Gln-Gln-Arg-Phe-Glu-Trp-Glu-Phe-Glu-Gln-Gln-NH2 (QQRFEWEFEQQ), CAS 593266-60-5, listed on cosmetic and drug labels under the INCI name oligopeptide-104. It is a structural biomaterial with no receptor, no systemic target and no endogenous human counterpart.
- Brand names
- Marketed as Curodont Repair (EU and Switzerland) and Curodont Repair Fluoride Plus (United States), both applied by a dental professional, and as Curodont Protect, a consumer dentifrice whose US label lists stannous fluoride as the active ingredient and oligopeptide-104 among the inactive ingredients. The underlying self-assembling-peptide platform is branded Curolox Technology. Invented and patented at the University of Leeds, licensed to credentis AG in Switzerland, now sold under the vVARDIS brand. Those are third-party trademarks. Medibact is not affiliated with, endorsed by, sponsored by or reselling any of them.
- What it is used for
- Guided remineralization of early, non-cavitated enamel caries and white-spot lesions, including the chalky white marks that develop around orthodontic brackets. It is not a treatment for a cavity that has already broken through the enamel surface.
- How it is applied
- In a dental chair, as part of a single appointment: the tooth is cleaned by prophylaxis, the lesion is conditioned and then etched so the peptide can pass through the intact surface layer, and the peptide solution is applied and left in place long enough to diffuse into the lesion body and assemble there. Fluoride varnish usually follows. Home-use gel and toothpaste formulations of the peptide also exist and are sold through ordinary retail channels.
- Evidence status
- Stronger human evidence than most compounds in peptide catalogues, with real caveats. A 2023 JADA systematic review and meta-analysis of six trials found substantially more caries arrest (relative risk 1.82, 95% CI 1.32-2.50; number needed to treat 2.8) and a mean 32% reduction in lesion size — while stating that all six trials carried elevated risk of bias and two used non-masked assessors. Two independent randomized trials did not place it ahead of modern fluoride varnishes.
- Regulatory status
- CE-marked as a medical device in the EU and Switzerland, permitting dentist use for early caries. In the United States the marketed product is an over-the-counter monograph anticaries drug whose recognized ACTIVE ingredient is sodium fluoride 0.05%; oligopeptide-104 appears among the INACTIVE ingredients with no stated amount. P11-4 itself holds no FDA approval and no identified 510(k) clearance.
- Half-life
- Not established, and not a meaningful parameter for this compound. There is no human pharmacokinetic data because it is never given systemically. The only retention data come from laboratory models, which report that a portion of the applied peptide remains inside the lesion as assembled scaffold.
- Sport
- Not on the WADA Prohibited List, including the 2026 List effective 1 January 2026, and there is no plausible basis for listing it — a topically applied dental material with no hormonal, metabolic or ergogenic mechanism does not fall under S2 or any other class.
- Availability and what Medibact sells
- Obtained through a dental practice, not sold to consumers as a standalone compound. Raw P11-4 is sold research-use-only by laboratory suppliers, explicitly not for human use. Medibact sells USP-grade bacteriostatic water and digital educational guides. Medibact does not sell peptides, and specifically does not sell P11-4 or any Curodont product.
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
P11-4 is a biomaterial rather than a signalling peptide, and that single distinction governs everything else about it. It binds no receptor, activates no pathway, has no systemic target and has no endogenous human counterpart. It is an eleven-residue sequence — Ac-Gln-Gln-Arg-Phe-Glu-Trp-Glu-Phe-Glu-Gln-Gln-NH2, written QQRFEWEFEQQ, CAS 593266-60-5 — that was designed at the University of Leeds to do one physical thing extremely reliably: assemble itself into a fibrous three-dimensional matrix when, and only when, it encounters a particular set of chemical conditions.
Those conditions are the ones found inside an early enamel lesion. Enamel demineralizes from the inside first: acid produced by plaque bacteria dissolves mineral in the subsurface body of the enamel while the outermost layer stays comparatively intact, leaving a porous, chalky, still-unbroken white area. That is what a white-spot lesion is, and that porous subsurface body is the target. P11-4 is supplied to the dentist as a monomeric solution — the peptide is held in its unassembled, free-flowing form, thin and mobile enough to diffuse through the pores of the intact surface layer and into the lesion body.
The trigger waiting inside the lesion is the lesion's own chemistry. A demineralized lesion is an acidic, ion-rich microenvironment, and it is that combination — low pH together with the elevated ionic strength of the dissolved mineral around it — that switches the peptide from monomer to matrix. Hierarchical self-assembly follows in stages: individual monomers align into antiparallel beta-sheet tapes, tapes stack into ribbons, ribbons into fibrils, and fibrils into fibres. Those stages proceed in that order, the lowest-order tapes forming first and the higher-order fibres taking longest to develop; no timescale is given here, because the published assembly kinetics come from laboratory systems rather than from a treated tooth. The result is a scaffold that structurally mimics the enamel matrix protein assemblies present when a tooth is first mineralized during development.
The direction of that pH trigger is worth stating explicitly, because it is frequently reported backwards. Assembly is switched on by acid, not by neutralization. The same acidity that created the lesion is what causes the peptide to gel and lock into place precisely where the damage is, and this is the whole basis of the design: the material is inert and mobile everywhere else in the mouth and becomes a solid scaffold only in the diseased volume. Assembly is pH-controlled, which is what gives the manufacturer control over where and when the matrix forms.
The assembled fibres carry regularly spaced anionic glutamate domains along their surfaces, and these act as high-affinity calcium nucleation sites. Calcium and phosphate ions already dissolved in saliva are captured at those sites, and hydroxyapatite crystals nucleate and grow de novo from within the lesion outward. This is the point most consumer coverage of Curodont gets wrong. P11-4 donates no mineral whatsoever. It contains no calcium, no phosphate and no fluoride. It is a nucleation template, and it is entirely dependent on the patient's own saliva to supply the raw material — which is also why saliva quality, diet and oral hygiene remain the limiting factors in whether the approach works for a given person. A secondary contribution is purely physical: the assembled matrix occludes lesion porosity, reducing the diffusive loss of mineral back out of the lesion. Laboratory work indicates that a portion of the applied peptide is retained inside the lesion as scaffold rather than being lost from it.
The rationale offered for why this differs from fluoride is spatial rather than chemical. Topical fluoride acts predominantly at the lesion surface, promoting formation of acid-resistant fluorapatite and tending to seal the outer layer; the mechanistic argument for P11-4 is that it seeds mineral growth throughout the body of the lesion instead. The two are not framed as competitors by the manufacturer — in the clinical trials and in the US formulation, the peptide is used alongside fluoride rather than instead of it.
One technical footnote is worth stating plainly, because it is central to why this compound is not a candidate for systemic use. The assembled, functional form of P11-4 is an engineered amyloid-like beta-sheet fibril. That structure is exactly what makes it work inside acellular enamel, where there are no cells to interact with it. It is also precisely the property that makes systemic administration a non-starter, and nobody has developed it for that purpose. There is no research programme, no trial and no published human data on parenteral P11-4 of any kind.
Researched effects
What P11-4 is meant to accomplish is narrow and specific: arrest and partial reversal of early enamel caries, without a drill and without removal of tooth structure. In practical terms the outcomes reported in trials fall into three categories. First, lesion activity — an active, chalky, rough white-spot lesion becoming inactive and hard on clinical assessment. Second, lesion size and mineral content — measurable shrinkage of the lesion area and increased mineral density on quantitative light-induced fluorescence, laser fluorescence or radiographic assessment. Third, appearance — white spots becoming less visually obvious as the enamel behind them regains mineral and its refractive index moves back toward that of sound enamel.
That third outcome is the one patients care about most and the one most likely to disappoint if expectations are not set carefully. Improvement in appearance is gradual, takes weeks to months as remineralization proceeds, and is partial rather than total in most reported cases. The mean lesion-size reduction across the pooled trials was 32%, with a standard deviation of 28% — a wide spread that reflects genuine variation in how individual lesions respond. This is not a cosmetic whitening product, it does not affect the colour of sound enamel, and it does nothing for staining, fluorosis or intrinsic discolouration.
The boundary of its usefulness is sharp and clinically important. P11-4 targets non-cavitated lesions, meaning the enamel surface must still be structurally intact. Once a lesion has cavitated — once the surface has collapsed and there is an actual hole — the porous diffusion pathway that the whole mechanism depends on no longer behaves the same way, and conventional restorative treatment is what is indicated. That is a determination a dentist makes by examination and radiograph, and it is the reason this is a prescribed clinical procedure rather than a consumer product. The pooled trial data reflect this boundary honestly: the meta-analysed reduction in cavitation had a confidence interval that crossed 1 (relative risk 0.32, 95% CI 0.10-1.06), so the claim that it prevents lesions from progressing to cavitation remains suggestive rather than established.
The most consistent finding across the trial base is the one on caries arrest, and it is a real effect: pooled relative risk 1.82 for lesion arrest with a number needed to treat of 2.8, meaning fewer than three lesions treated for one additional arrested lesion compared with control. A 2024 randomized trial in Clinical Oral Investigations reported substantially less lesion progression with the peptide-plus-fluoride product than with sodium fluoride varnish over six months. A triple-blind trial published in BMC Oral Health in 2026, of a home-use peptide-plus-fluoride gel used during fixed orthodontic treatment, found initial lesions on 7.2% of surfaces versus 14.5% with the control gel over eighteen months.
What P11-4 does not do is equally worth stating. It does not regrow enamel that has been lost to cavitation or fracture, it does not replace fillings, it does not treat dentine caries, it does not affect gum disease, and it has no systemic effect of any kind — no metabolic, hormonal, recovery, cognitive, cosmetic or performance action. Every clinical effect attributed to it happens inside a few hundred microns of one tooth surface.
Evidence & regulatory status
- Keeper et al., Journal of the American Dental Association, 2023;154(7):580-591.e11 — systematic review and meta-analysis pooling six clinical trials of the P11-4 product. Found a large increase in caries arrest (RR 1.82, 95% CI 1.32-2.50; NNT 2.8) and a mean 32% (SD 28%) reduction in lesion size. The cavitation estimate was favourable but imprecise, with a confidence interval crossing 1 (RR 0.32, 95% CI 0.10-1.06), and merged-ICDAS improvement was highly uncertain (RR 3.68, 95% CI 0.42-32.3). The reviewers explicitly stated that two trials used non-masked assessors, that ALL included trials carried elevated risk of bias, and that longer trials are needed. This is the single most important reference on the compound, and its caveats are as load-bearing as its point estimates.
- Alkilzy et al., 2018 — randomized comparison of P11-4 plus fluoride against fluoride alone, reporting superior laser fluorescence readings and greater ICDAS regression in the peptide arm. Notable for testing the combination rather than the peptide in isolation, which is how the product is actually used.
- Doberdoli et al., Scientific Reports 2020;10:4195 — a three-arm, patient-blinded randomized trial in 90 children and adolescents with early occlusal caries, comparing fluoride varnish alone against P11-4 plus fluoride varnish and against P11-4 with a peptide-matrix preventive gel. Scored on the Nyvad caries activity criteria at twelve months, every assessed lesion in both peptide arms was rated inactive — 27 of 27 in each arm, 54 of 54 in total — against 13 of 23 in the control arm, and laser fluorescence values fell in both peptide arms while rising in the control arm. That complete-inactivation result is real and correctly cited, but it should be read for what it is: a striking effect size in a small trial, in a lesion type where activity assessment rests partly on the examiner's tactile and visual judgement.
- Broseler et al., 2020 and Sedlakova et al., 2020 — two randomized trials reporting significant lesion-size reduction against fluoride varnish and against placebo respectively. These, with the studies above, form the bulk of the JADA meta-analysis pool.
- Shaalan, Fawzy El-Sayed and Abouauf, Clinical Oral Investigations, 2024;28:438 — randomized controlled trial in 28 participants with 58 incipient lesions, comparing the US peptide-plus-fluoride formulation against a sodium fluoride varnish, with two calibrated and blinded assessors using a laser fluorescence device at one, three and six months. The peptide arm showed markedly less lesion progression and more improvement than the varnish arm. Single centre, small sample, six-month follow-up, and a surrogate measurement endpoint rather than a clinical one.
- BMC Oral Health, 2026;26:379 — prospective triple-blind randomized trial of a home-use gel combining P11-4 with approximately 900 ppm sodium monofluorophosphate, applied twice weekly during multibracket orthodontic treatment in 25 patients aged 11-17 over 18 months. Initial lesions (ICDAS 1 or 2) developed on 7.2% of surfaces versus 14.5% in the placebo arm, with no adverse effects reported. Methodologically among the better entries in the literature — triple-blind and with the longest follow-up available — though still only 25 participants.
- NEGATIVE DATA, stated because omitting it would misrepresent the field: a randomized trial published in BMC Oral Health comparing P11-4, nano-silver fluoride and sodium fluoride varnish reported ICDAS reduction with P11-4 that was not significantly different from plain sodium fluoride varnish. A 2025 triple-blind randomized trial in BDJ Open, in children aged 8-12, compared P11-4 against 2% arginine-enriched sodium fluoride and functionalized tricalcium-phosphate fluoride varnish and reported P11-4 performing least well of the three. The fair reading of the whole literature is that P11-4 beats plain fluoride varnish in several trials but is not clearly superior to newer fluoride-plus formulations.
- Conflict-of-interest context, which readers should weigh directly: the trial base is closely tied to the patent-holding university and to the manufacturer, with at least one trial sponsor classified as INDUSTRY on ClinicalTrials.gov. Sample sizes across the literature run from roughly 25 to 90 subjects, and follow-up runs three to eighteen months. There are no retractions and no identified safety signals — the risk in this evidence base is overstatement, not misconduct.
- IN VITRO — extensive and consistently favourable: laboratory models report substantial recovery of mineral density in artificial enamel lesions, with more uniform mineral deposition than casein phosphopeptide-amorphous calcium phosphate comparators, and retention of part of the applied peptide within the lesion as assembled scaffold. In vitro enamel models are well established but remove saliva dynamics, diet, plaque and patient behaviour, which is precisely where clinical effect sizes shrink.
- ANIMAL — one small-animal study exists outside the dental-enamel setting: a rat periodontal defect model in which a hydrogel form of the peptide was placed into surgically created defects, reporting increased functional periodontal ligament length, reduced epithelial downgrowth, higher osteocalcin and osteoprotegerin, and no local adverse reactions. A wider preclinical literature exists on P11-family self-assembling peptide hydrogels as locally placed scaffolds for bone and cartilage tissue engineering. All of it is in vitro or small-animal, all of it treats the material as a scaffold occupying a local defect, and none of it involves systemic administration or human subjects. No formulation detail from that work is reproduced here, and none of it establishes anything about human use.
- HUMAN DATA ON ANY NON-ORAL ROUTE: none. Zero. There is no human pharmacokinetic study, no human systemic safety study, and no human trial of P11-4 by any route other than topical application to the mouth.
A printable reference sheet and log comes with All-Access Lifetime.
Half-life & pharmacokinetics
Not established, and not a meaningful parameter for this compound. There is no published human pharmacokinetic data for P11-4 — no plasma half-life, no Cmax, no clearance, no volume of distribution — for the straightforward reason that it is never administered systemically and its systemic absorption has never been characterized. Any figure quoted as a half-life for P11-4 has been invented or borrowed from an unrelated peptide.
The parameter that actually matters for a scaffold biomaterial is retention at the site of action, not clearance from plasma, and there the literature offers only laboratory observations: in artificial-lesion models a portion of the applied peptide is retained within the lesion as assembled scaffold. The scaffold is intended to persist inside the lesion over the weeks during which remineralization proceeds, which is why clinical outcomes are assessed at three, six, twelve and eighteen months rather than in hours. The manufacturer's safety rationale for the fraction that is not retained is that swallowed material is broken down to its constituent amino acids or excreted — a reasonable expectation for a short peptide passing through the gut, though it is a rationale rather than a measured pharmacokinetic result.
The practical takeaway is that duration of action for P11-4 is a question about how long a mineral scaffold survives inside a tooth, not a question about circulating concentrations, and it should not be compared with the half-life figures published for systemic peptides.
Side effects, safety & contraindications
The clinical tolerability record is genuinely clean, and it should be read with its boundaries clearly marked. Across the in vivo clinical studies, no adverse events, medical complications or allergic reactions were reported, with follow-up to twelve months in the review literature and eighteen months in the 2026 orthodontic trial, whose authors state that no adverse effects were reported by any patient. Regulatory biocompatibility testing to ISO 10993 or equivalent standards showed no cytotoxicity and no immunologic response. The risk profile is characterized as minor for a defensible structural reason: the target tissue, enamel, is acellular, so there is no cellular machinery at the site of action for the material to disturb.
Four caveats belong alongside that record.
First, the trial populations are small — tens of subjects per study — so rare, idiosyncratic or delayed events would not be detected by this evidence base. A clean record across a few hundred treated patients establishes that common adverse effects are unlikely; it does not establish that uncommon ones do not exist.
Second, several of the risks associated with the procedure are not risks of the peptide at all. The conditioning and acid-etching steps that prepare the lesion use caustic agents and carry the usual soft-tissue irritation and chemical-burn risks common to any acid-etch dental procedure. Managing those is the practitioner's responsibility and depends on isolation, technique and clinical judgement rather than on anything about the peptide.
Third, the US formulation is not peptide alone. The active ingredient recognized on the Curodont Repair Fluoride Plus label is sodium fluoride, and its inactive ingredients include water, chlorhexidine digluconate, tromethamine, trehalose dihydrate and oligopeptide-104 — the peptide itself. Both of the pharmacologically familiar components carry their own established considerations: fluoride exposure limits are relevant in young children, and chlorhexidine digluconate is associated with extrinsic tooth staining, taste alteration and, rarely, hypersensitivity reactions. Anyone with a known chlorhexidine allergy needs the practice to know before treatment.
Fourth, and most important for readers who came from a peptide catalogue: the assembled species is an engineered amyloid-like beta-sheet fibril. That is benign in acellular enamel. There is no human data whatsoever on parenteral exposure to this compound, so nothing at all can be said about systemic safety — not that it is safe, not that it is unsafe. The favourable dental safety record is a record about a topical dental procedure and does not extend one millimetre beyond it.
Storage & handling
- No patient-side storage question arises for the clinical product. Curodont Repair and Curodont Repair Fluoride Plus are supplied as sealed single-use kits held by the dental practice and applied in the chair, and storage and shelf-life follow the manufacturer's labelling and the practice's own materials handling — not anything a patient does at home.
- Home-use formulations — the peptide-plus-monofluorophosphate gel tested in the orthodontic trial, and Curodont Protect, a consumer dentifrice whose US label lists stannous fluoride as the active ingredient and oligopeptide-104 among the inactive ingredients — are ordinary consumer oral-care products stored according to their own package labelling, in the same way as any toothpaste or dental gel.
- Bacteriostatic water plays no part in the handling of this compound at any stage. It is not reconstituted, so the benzyl-alcohol preservative logic that governs multi-withdrawal peptide vials is simply not relevant here, and none of Medibact's bacteriostatic water guidance applies to P11-4.
- Research-use-only lyophilized P11-4 sold by laboratory suppliers is stored and handled according to that supplier's certificate of analysis and safety data sheet. It is labelled explicitly not for human use, the guidance issued with it is benchwork guidance for in vitro experiments rather than a preparation protocol for anything given to a person, and no part of it is reproduced on this page.
- The reason the marketed product ships finished rather than as a powder to be mixed is the peptide's defining property: it is engineered to stay unassembled until it meets the conditions inside a lesion, and holding it reliably in that unassembled state is a formulation problem the manufacturer has solved in the factory. That is why the dental product exists as a ready-to-use unit, why there is nothing for a practice or a patient to prepare, and why no mixing step exists anywhere in its legitimate use.
References
The central human reference is the 2023 systematic review and meta-analysis published in the Journal of the American Dental Association (2023;154(7):580-591.e11), first-authored by Keeper, pooling six clinical trials of the P11-4 product. Readers evaluating this compound should read that paper's risk-of-bias section as carefully as its effect estimates: it reports substantially increased caries arrest (RR 1.82, 95% CI 1.32-2.50; NNT 2.8) and a mean 32% lesion-size reduction, while stating that all six included trials carried elevated risk of bias and two used non-masked assessors, and it explicitly calls for longer trials. The named individual trials underlying it include Alkilzy et al. 2018 (peptide plus fluoride versus fluoride alone), Doberdoli et al., Scientific Reports 2020;10:4195 (three-arm patient-blinded trial in 90 children and adolescents with early occlusal caries, in which all 54 assessed peptide-treated lesions, 27 in each of the two peptide arms, were rated inactive on the Nyvad criteria at twelve months, against 13 of 23 controls), and Broseler et al. 2020 and Sedlakova et al. 2020 (lesion-size reduction against fluoride varnish and placebo). Two more recent trials sit outside that pool: Shaalan, Fawzy El-Sayed and Abouauf, Clinical Oral Investigations 2024;28:438 (28 participants, 58 incipient lesions, blinded laser-fluorescence assessment to six months, favouring the peptide-plus-fluoride product over sodium fluoride varnish), and a prospective triple-blind randomized trial in BMC Oral Health 2026;26:379 of a home-use peptide-plus-monofluorophosphate gel during multibracket orthodontic treatment (25 patients aged 11-17, 18 months, initial lesions on 7.2% of surfaces versus 14.5% in the placebo arm). The unfavourable literature must be read alongside it: a randomized trial in BMC Oral Health comparing P11-4, nano-silver fluoride and sodium fluoride found no significant ICDAS difference against plain sodium fluoride varnish, and a 2025 triple-blind trial in BDJ Open in children aged 8-12 reported P11-4 performing least well against 2% arginine-enriched sodium fluoride and functionalized tricalcium-phosphate fluoride varnish. Trial sponsorship is relevant context: at least one trial sponsor is classified as INDUSTRY on ClinicalTrials.gov, and the trial base as a whole is closely connected to the patent-holding institution and the licensee.
Regulatory and practice-scope facts can be verified directly. The US product listing appears on DailyMed under labeler CREDENTIS AG, showing sodium fluoride 0.05% as the active ingredient under the OTC anticaries monograph, with the inactive ingredients including water, chlorhexidine digluconate, tromethamine, trehalose dihydrate and oligopeptide-104. European and Swiss status rests on a CE mark as a medical device. The delegation question is addressed in the North Carolina State Board of Dental Examiners interpretive statement dated 18 October 2024, published on the board's website at ncdentalboard.org, which permits a dental hygienist to apply the product only after prophylaxis and only where a dentist has examined the patient and prescribed the application. Anti-doping status can be checked against the WADA Prohibited List, including the 2026 List effective 1 January 2026, on which the compound does not appear.
Trademark and affiliation notice: Curodont, Curodont Repair, Curodont Repair Fluoride Plus, Curodont Protect, Curolox and vVARDIS are trademarks of their respective owners. Medibact is not affiliated with, endorsed by, sponsored by or authorized by vVARDIS, credentis AG or the University of Leeds, does not distribute or resell any product referenced on this page, and receives no compensation in connection with them. Brand names are used here descriptively, because they are how the underlying technology is identified in the real world, and their use does not imply any relationship.
This guide is educational content for informational purposes only, and it is free in full — there is no paid tier, protocol sheet or product associated with it. Medibact sells USP-grade bacteriostatic water and digital educational guides; it does not sell peptides, and it does not sell P11-4 or any Curodont product. Nothing here is medical or dental advice, a diagnosis, a treatment recommendation or a personalized protocol. P11-4 is not injected in humans, there is no human injectable dose, route or safety data for it, and this page deliberately publishes no concentration, solvent or preparation figure for the raw peptide, so nothing on it should be read as describing or implying an injection protocol. The clinical application procedure involves caustic conditioning and etching agents applied to a patient's tooth and is a dentist-prescribed clinical procedure; its reagents and timings are deliberately not reproduced here, and attempting it outside a dental setting would be unsafe and in most jurisdictions unlawful. Anyone with white-spot lesions or early caries should consult a qualified dental professional.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Guide FAQ
Quick answers about guide scope, access, and educational use context.
What is Curodont, and what does it have to do with P11-4?
Curodont is the brand name under which the P11-4 peptide is sold as a dental product. P11-4 is the peptide itself — eleven amino acids, sequence QQRFEWEFEQQ, listed on product labels under its INCI name oligopeptide-104. It was invented and patented at the University of Leeds in the UK, exclusively licensed to credentis AG in Switzerland, and is now marketed under the vVARDIS brand. The main product names are Curodont Repair in the EU and Switzerland and Curodont Repair Fluoride Plus in the United States, both applied by a dental professional, and Curodont Protect, a consumer dentifrice whose US label lists stannous fluoride as the active ingredient and oligopeptide-104 among the inactive ingredients. The underlying peptide platform is branded Curolox Technology. Curodont, Curolox and vVARDIS are third-party trademarks belonging to their owners. Medibact is not affiliated with, endorsed by or sponsored by vVARDIS, credentis or the University of Leeds, does not resell any Curodont product, and has no commercial relationship with any of them. This page describes the brand because it is what people search for, and for no other reason.
Is P11-4 an injectable peptide?
No, and this is the most important thing on the page. P11-4 is not injected in humans under any protocol, approved or otherwise. There is no subcutaneous, intramuscular or intravenous dose for it, no reconstitution procedure, no human pharmacokinetic data and no systemic safety data of any kind. Every human study of this compound has used topical application inside the mouth. The confusion is understandable — it is a peptide, it is sold as a lyophilized powder to laboratories for research use, and it appears in peptide reference lists alongside compounds that are reconstituted and injected — but the resemblance ends at the word 'peptide'. P11-4 is a biomaterial with no receptor, no signalling function and no systemic target; its functional form is an engineered amyloid-like fibril that assembles when the monomer meets the acidic, ion-rich conditions inside a tooth lesion. The nearest thing to an injection anywhere in its literature is a preclinical rat study in which a hydrogel form of the peptide was placed into surgically created periodontal defects, where it acted as a locally sited scaffold rather than a systemically distributed drug. Nobody has developed this compound for systemic use, and there is no basis on which any injection quantity could be described as safe.
Does Curodont actually work?
The honest answer is a qualified yes, with limits that most coverage skips. The strongest evidence is a 2023 systematic review and meta-analysis in the Journal of the American Dental Association, which pooled six clinical trials and found a substantial increase in caries arrest — relative risk 1.82, 95% CI 1.32 to 2.50, a number needed to treat of 2.8 — and a mean 32% reduction in lesion size. That is a real effect and better human evidence than most compounds discussed in peptide circles ever accumulate. The limits are equally real. The same review stated that all six included trials carried elevated risk of bias and two used non-masked assessors. The cavitation estimate had a confidence interval crossing 1, so it is not conclusive. Trial sizes run from roughly 25 to 90 subjects and follow-up from three to eighteen months. The trial base is closely tied to the patent-holding university and the manufacturer, with at least one trial industry-sponsored. And two independent randomized trials were unfavourable: one found no significant difference in ICDAS reduction against plain sodium fluoride varnish, and a 2025 triple-blind trial in children reported P11-4 performing least well against arginine-enriched sodium fluoride and functionalized tricalcium-phosphate fluoride varnishes. The fair summary is that it works, that it outperformed plain fluoride varnish in several trials, and that it is not clearly better than newer fluoride-plus formulations.
What are Curodont's side effects?
Across the clinical studies, no adverse events, medical complications or allergic reactions were reported, with follow-up to twelve months in the review literature and eighteen months in the longest trial, where investigators recorded no adverse effects in any patient. Biocompatibility testing showed no cytotoxicity and no immunologic response, which is unsurprising given that the target tissue — enamel — has no cells. Four qualifications belong with that. Trial populations number in the tens, so rare or delayed events would not have been detected. The procedure itself involves conditioning and acid-etching the lesion with caustic agents, which carry the ordinary soft-tissue irritation risks of any acid-etch dental procedure and depend on the practitioner's isolation and technique rather than on the peptide. The US formulation lists sodium fluoride as its active ingredient and includes chlorhexidine digluconate among its inactive ingredients, so fluoride exposure limits matter in young children, and chlorhexidine digluconate brings its own known issues with extrinsic staining, taste alteration and rare hypersensitivity. And there is no human safety data of any kind for exposure by any route other than topical oral application, so nothing about systemic safety can be inferred from this record.
Is Curodont FDA approved?
No, and the precise situation is the single most frequently misreported fact about this compound. In the EU and Switzerland the product is CE-marked as a medical device, which permits dentists to use it for early caries and similar defects — a device CE mark, not a drug approval. In the United States, P11-4 itself has no FDA approval and no identified 510(k) clearance. The US product, Curodont Repair Fluoride Plus, is listed on DailyMed as an over-the-counter monograph drug under the anticaries monograph, and its ACTIVE ingredient is sodium fluoride 0.05%, equivalent to 0.02% w/v fluoride ion. Oligopeptide-104 — the peptide — appears on that label among the INACTIVE ingredients, with no stated amount, alongside water, chlorhexidine digluconate, tromethamine and trehalose dihydrate. In regulatory terms, therefore, the therapeutic agent FDA recognizes in the US product is fluoride, and the peptide is formally an excipient whose efficacy FDA has never evaluated. Over-the-counter monograph products also carry the standard DailyMed statement that FDA has not evaluated whether the product complies. None of that means the peptide does nothing — the clinical trials are what they are — but it does mean US regulatory status offers no endorsement of the peptide's effect. Raw P11-4 sold by laboratory suppliers is research-use-only and explicitly not for human use, and no regulator anywhere has approved it for injection or systemic administration.
How much does Curodont Repair cost, and where is it available?
There is no verified public price schedule, and this page will not guess at one. It is a professionally applied procedure priced by the individual dental practice, and pricing generally varies with the number of lesions treated, whether it is bundled with a prophylaxis appointment and fluoride varnish, and regional cost of care. Because the US product sits in the over-the-counter monograph category rather than being an approved therapeutic device or drug for caries reversal, coverage by dental insurance is inconsistent and frequently absent, so it is commonly an out-of-pocket item. Availability is through dental practices that have chosen to stock it rather than through pharmacies or consumer channels; the manufacturer's own practitioner locator and a direct call to a local practice are the practical routes to a current price. The related consumer products — peptide-containing home gels, and Curodont Protect, a consumer dentifrice whose US label lists stannous fluoride as the active ingredient and oligopeptide-104 among the inactive ingredients — are sold through ordinary retail channels at ordinary oral-care price points. Medibact does not sell, resell or broker any of these products and has no pricing relationship with the manufacturer.
What is oligopeptide-104?
Oligopeptide-104 is the INCI name for P11-4 — the standardized ingredient-labelling name used on cosmetic and drug labels, which is why it is the form that appears on a US product carton rather than 'P11-4'. The two terms refer to exactly the same eleven-residue molecule, Ac-Gln-Gln-Arg-Phe-Glu-Trp-Glu-Phe-Glu-Gln-Gln-NH2, CAS 593266-60-5. Seeing it in an inactive-ingredient list is not a sign that a product contains a trace or a marketing flourish; in the US formulation it is the peptide that the clinical trials studied, listed as inactive because FDA's monograph framework recognizes only the sodium fluoride as the active anticaries ingredient. Readers scanning ingredient lists should also note that oligopeptide-104 is distinct from the numbered oligopeptides used in skincare, which are unrelated sequences that share only a naming convention.
Can P11-4 repair an existing cavity or regrow lost enamel?
No. The mechanism depends on diffusing through an intact enamel surface into a porous subsurface lesion, so the target is an early, non-cavitated lesion — a white spot or an incipient carious lesion where the surface has not yet collapsed. Once a lesion has cavitated and there is an actual hole, conventional restorative treatment is what is indicated, and the pooled trial data reflect that boundary honestly: the meta-analysed reduction in cavitation had a confidence interval crossing 1 and is therefore not conclusive. P11-4 also does not regrow enamel lost to wear, fracture or erosion, does not treat dentine caries, does not replace fillings and does nothing for gum disease. Whether a particular lesion falls inside the treatable category is a clinical determination made by examination and radiograph, not something that can be judged from a photograph or a mirror — which is a large part of why this is a dentist-prescribed procedure rather than a consumer product.
Why does P11-4 assemble inside the lesion and not everywhere else in the mouth?
Because the trigger is the lesion's own acidity. The peptide is supplied in a monomeric, free-flowing form and stays that way while it is being applied and while it diffuses through the pores of the intact enamel surface. Inside a demineralized lesion it meets a low-pH, ion-rich microenvironment, and that combination flips it into hierarchical self-assembly — tapes, then ribbons, then fibrils and fibres — so the solid scaffold forms in the diseased volume rather than on healthy enamel or soft tissue. This direction is often reported backwards in consumer coverage, which describes the peptide as assembling when it reaches a more neutral or alkaline environment. It is the opposite: assembly is switched on by acid. That is the elegance of the design, and it is also why the material is described as pH-controlled — the same chemistry that caused the lesion is what recruits the repair scaffold to it.
Is P11-4 banned in sport?
No. P11-4 and oligopeptide-104 do not appear on the WADA Prohibited List, including the 2026 List effective 1 January 2026, and the compound does not fall under S2 — peptide hormones, growth factors, related substances and mimetics — or under any other class. The reason is structural rather than administrative: it is a topically applied, non-systemic dental biomaterial with no hormonal, metabolic or ergogenic mechanism and no systemic distribution at all. The accurate framing is that it is not listed and has no plausible basis for being listed, rather than that any anti-doping authority has issued a ruling about it. Athletes with questions about any specific product formulation, which may contain fluoride and chlorhexidine digluconate alongside the peptide, should still confirm the full ingredient list with their own anti-doping advisers as a matter of routine.
Does Medibact sell P11-4 or Curodont?
No. Medibact sells USP-grade bacteriostatic water and digital educational guides. It does not sell peptides of any kind, and it specifically does not sell P11-4, oligopeptide-104, or any Curodont, Curolox or vVARDIS product, and has no affiliation or commercial relationship with the companies that do. This page exists for two reasons. First, a very large number of people search for Curodont every month and deserve a plain-English explanation of what it is, how it works and what the trials genuinely show — including the unfavourable ones. Second, and more specifically, anyone who encountered P11-4 in a research-peptide context needs to know clearly that it is not an injectable compound, that no injectable protocol exists, and that no reconstitution figures should be inferred for it. This guide is free in full, with no paid tier, no protocol sheet and no product attached, because there is nothing here to sell.
Compliance and trust notes
- Educational content only; no personalized health or outcome claims.
- No personalized use recommendation outputs.
- Use this material for general learning and research-context literacy.
